NeuroDiscovery AI Launches NeuroTerminal Platform to Accelerate Neurological Clinical Trial Recruitment
Key Insights
NeuroDiscovery AI (search) announced the launch of NeuroTerminal (search), a neurology-specific AI platform designed to dramatically reduce clinical trial recruitment time from months to weeks.
The platform leverages over 6 million de-identified longitudinal neurology patient journeys and 3 million clinical-trials-ready patients across 100+ clinical sites in 16 U.S. states.
NeuroTerminal (search) addresses recruitment bottlenecks for neurological disorders including Alzheimer's disease (search), Parkinson's disease (search), multiple sclerosis (search), epilepsy (search), and rare neurological conditions.
NeuroDiscovery AI (search) announced the launch of NeuroTerminal (search), a purpose-built life sciences platform specifically designed for neurology that promises to dramatically reduce clinical trial recruitment timelines. The platform addresses one of the most significant bottlenecks in neurological drug development by leveraging artificial intelligence to identify and screen patients for clinical trials in weeks rather than months.
Addressing Critical Recruitment Challenges
Clinical trial recruitment represents a major obstacle in neurological drug development, with traditional methods requiring months to identify appropriate patients. "Clinical trial recruitment remains one of the largest bottlenecks in drug development, particularly in neurology where it can take many months to identify and screen the right patients," said Vamsi Chandra Kasivajjala, founder and CEO of NeuroDiscovery AI (search). "Our platform is able to reduce that timeline to mere weeks, which can mean earlier access to research opportunities and therapies that may improve a patient's quality of life."
NeuroTerminal (search) brings together dedicated modules for clinical trials, real-world evidence, medical affairs and real-world data, specifically targeting neurological disorders including Alzheimer's disease (search), Parkinson's disease (search), migraine (search), multiple sclerosis (search), epilepsy (search), and rare and ultra-rare neurological conditions.
Comprehensive Data Infrastructure
The platform operates on one of the largest neurology-focused real-world datasets in the United States, encompassing:
- 6+ million de-identified longitudinal neurology patient journeys
- 3+ million active clinical-trials-ready patients
- 100+ clinical sites across 16 U.S. states
- A network of more than 1,000 neurologists and advanced practice providers
Unlike generalized healthcare AI platforms, NeuroTerminal (search) was purpose-built around the complexity and longitudinal nature of neurological disease progression. The platform combines real-world data, provider-embedded workflows, and NeuroLLM™, the company's proprietary AI model, to analyze electronic health records, clinical notes, diagnostic histories, medications, lab results, cognitive assessments, 'OMICS' test results, imaging data, and treatment histories curated across more than 15 years of longitudinal neurology care.
Provider-Centric Development Approach
The platform's development involved direct collaboration with neurology providers to ensure practical clinical utility. "NeuroDiscovery AI (search) was built alongside neurology providers, not in isolation," explained Dr. Laszlo L. Mechtler, a board-certified neurologist and strategic advisor to NeuroDiscovery AI. "Neurology practices asked for better ways to understand and act on their own data, and NeuroDiscovery AI met that request. This provides a continuous feedback loop to refine the platform around the realities of clinical care and help change the trajectory of neurological disease."
Expanding Beyond Recruitment
Beyond clinical trial recruitment, NeuroTerminal (search) supports real-world data licensing, real-world evidence generation, provider engagement, implementation sciences, and commercialization support. The platform also helps reduce manual chart review burdens for providers while increasing the likelihood that patients are identified for relevant research opportunities and therapies.
The company is currently supporting collaborations across pharmaceutical sponsors, clinical research organizations, and neurology providers focused on accelerating research, improving trial efficiency, and expanding access to emerging therapies for neurodegenerative disease.